

# Hiroshi Aikata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4027995/publications.pdf>

Version: 2024-02-01

195  
papers

5,265  
citations

101384

36  
h-index

123241

61  
g-index

198  
all docs

198  
docs citations

198  
times ranked

7167  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. <i>Journal of Infectious Diseases</i> , 2023, 227, 686-695.	1.9	1
2	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
3	The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675.	1.1	4
4	A patient with chronic hepatitis B who developed hepatocellular carcinoma with hypervascularity in 9 years of close follow-up. <i>Acta Hepatologica Japonica</i> , 2022, 63, 24-34.	0.0	0
5	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	1.4	5
6	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 354-367.	4.2	44
7	Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2022, 22, 414-420.	0.5	6
8	Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients. <i>Journal of Infection</i> , 2022, 84, 391-399.	1.7	3
9	Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the <i>ATP8B1</i> Gene. <i>Case Reports in Gastroenterology</i> , 2022, 16, 110-115.	0.3	1
10	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340.	4.2	5
11	The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 443-450.	0.6	2
12	Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
13	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
14	A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death. <i>Acta Hepatologica Japonica</i> , 2022, 63, 279-285.	0.0	0
15	Exacerbation of Portal Hypertensive Enteropathy after Endoscopic Injection Sclerotherapy for Esophageal Varices. <i>Digestion</i> , 2021, 102, 188-196.	1.2	4
16	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 538-547.	1.0	3
17	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	1.0	1
18	A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 283-287.	0.4	14

#	ARTICLE	IF	CITATIONS
19	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	1.4	5
20	A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system. <i>IDCases</i> , 2021, 23, e01059.	0.4	0
21	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
22	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	0.9	5
23	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
24	A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. <i>Acta Hepatologica Japonica</i> , 2021, 62, 136-143.	0.0	0
25	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.3	2
26	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	1.7	8
27	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.0	0
28	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. <i>BMC Cancer</i> , 2021, 21, 668.	1.1	6
29	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	3.5	23
30	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	1.0	0
31	Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1304-1311.	1.0	2
32	Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1517-1524.	0.4	0
33	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
34	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.3	1
35	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	1.7	29
36	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20

#	ARTICLE	IF	CITATIONS
37	Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1268-1275.	1.1	8
38	Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. <i>Medicine (United States)</i> , 2021, 100, e27576.	0.4	8
39	Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.4	3
40	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	2.3	16
41	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. <i>Journal of Medical Virology</i> , 2020, 92, 210-218.	2.5	5
42	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	1.4	10
43	Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 421-427.	0.4	2
44	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.3	3
45	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	4.2	27
46	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
47	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	1.8	15
48	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	4.2	71
49	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	0.8	8
50	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. <i>Hepatology Research</i> , 2020, 50, 1222-1233.	1.8	13
51	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	0.9	8
52	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Gastroenterology</i> , 2020, 55, 1162-1170.	2.3	9
53	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	1.8	0
54	Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution. <i>Journal of Gastroenterology</i> , 2020, 55, 877-887.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	1.4	11
56	Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1. <i>Journal of Infectious Diseases</i> , 2020, 222, 2061-2070.	1.9	10
57	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	1.3	37
58	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
59	Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. <i>EBioMedicine</i> , 2020, 53, 102659.	2.7	48
60	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.4	3
61	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
62	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
63	<i>In vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	5
64	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	1.6	13
65	Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81.	0.9	44
66	Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2019, 19, 169.	0.8	14
67	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.4	6
68	Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	2.0	43
69	Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2019, 54, 650-659.	2.3	6
70	The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. <i>Journal of Medical Virology</i> , 2019, 91, 650-658.	2.5	26
71	Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. <i>Journal of Gastroenterology</i> , 2019, 54, 291-296.	2.3	39
72	Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. <i>Journal of General Virology</i> , 2019, 100, 1123-1131.	1.3	6

#	ARTICLE	IF	CITATIONS
73	A case of primary hepatic leiomyosarcoma. <i>Acta Hepatologica Japonica</i> , 2019, 60, 358-365.	0.0	1
74	Predictive Factors of Portal Hypertensive Enteropathy Exacerbation in Patients with Liver Cirrhosis: A Capsule Endoscopy Study. <i>Digestion</i> , 2018, 98, 33-40.	1.2	6
75	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
76	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28
77	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
78	Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology</i> , 2018, 53, 107-118.	2.3	17
79	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, 51-58.	1.8	110
80	Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 193-204.	1.8	16
81	Involvement of <i>Porphyromonas gingivalis</i> in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 269-280.	2.3	73
82	Clinical significance of small bowel villous edema in patients with liver cirrhosis: A capsule endoscopy study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 825-830.	1.4	4
83	Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. <i>Hepatology Research</i> , 2018, 48, 264-274.	1.8	3
84	Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival. <i>European Journal of Radiology</i> , 2018, 98, 41-49.	1.2	17
85	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.2	4
86	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. <i>Virology</i> , 2018, 525, 48-61.	1.1	20
87	Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study. <i>Antiviral Therapy</i> , 2018, 23, 639-646.	0.6	9
88	Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 152-157.	1.0	15
89	CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1555-1564.	1.0	6
90	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1834-1840.	2.5	12

#	ARTICLE	IF	CITATIONS
91	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS ONE, 2018, 13, e0195028.	1.1	21
92	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatology Research, 2018, 48, 1118-1130.	1.8	13
93	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer, 2018, 18, 633.	1.1	17
94	A case of primary hepatic angiosarcoma evaluated by contrast-enhanced ultrasonography. Choonpa Igaku, 2018, 45, 215-221.	0.0	0
95	<i>IFNL4</i> polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. Hepatology Research, 2017, 47, E5-E13.	1.8	4
96	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. Clinical Journal of Gastroenterology, 2017, 10, 179-184.	0.4	2
97	Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. Oncology, 2017, 92, 335-346.	0.9	11
98	Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. Hepatology Research, 2017, 47, 1053-1060.	1.8	11
99	<i>Wisteria floribunda</i> agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. Journal of Gastroenterology, 2017, 52, 1252-1257.	2.3	27
100	Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia. Clinical Journal of Gastroenterology, 2017, 10, 383-387.	0.4	12
101	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. Antiviral Therapy, 2017, 23, 239-248.	0.6	8
102	Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 279-288.	0.6	45
103	Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
104	Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery, 2017, 44, 223-228.	1.1	40
105	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. Journal of Medical Virology, 2017, 89, 1963-1972.	2.5	11
106	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. Journal of Gastroenterology, 2017, 52, 746-753.	2.3	19
107	Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. Journal of Hepatology, 2017, 66, 363-373.	1.8	81
108	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 645-650.	1.4	11

#	ARTICLE	IF	CITATIONS
109	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 253-262.	2.3	4
110	Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. <i>Hepatology Research</i> , 2017, 47, 767-772.	1.8	15
111	The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. <i>Journal of Gastroenterology</i> , 2017, 52, 366-375.	2.3	12
112	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. <i>Journal of Medical Virology</i> , 2017, 89, 665-671.	2.5	9
113	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511.	2.3	16
114	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. <i>PLoS ONE</i> , 2017, 12, e0182710.	1.1	44
115	Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. <i>Journal of General Virology</i> , 2017, 98, 1040-1047.	1.3	17
116	Third-Generation Capsule Endoscopy Outperforms Second-Generation Based on the Detectability of Esophageal Varices. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	19
117	Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 524-530.	0.5	38
118	Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. <i>Hepatology Research</i> , 2016, 46, 707-712.	1.8	11
119	Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 758-764.	1.8	60
120	Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. <i>Hepatology Research</i> , 2016, 46, 1402-1408.	1.8	9
121	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2016, 46, E146-53.	1.8	19
122	Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. <i>Hepatology Research</i> , 2016, 46, 944-948.	1.8	21
123	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. <i>Nature Genetics</i> , 2016, 48, 500-509.	9.4	596
124	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, 1256-1263.	1.8	7
125	Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1009-1015.	1.4	52
126	Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. <i>Journal of Gastroenterology</i> , 2016, 51, 1073-1080.	2.3	21



#	ARTICLE	IF	CITATIONS
127	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
128	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. <i>Anticancer Research</i> , 2016, 36, 3523-9.	0.5	21
129	Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report. <i>Hepatology Research</i> , 2015, 45, 705-710.	1.8	5
130	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , 2015, 45, 1047-1054.	1.8	16
131	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	1.8	42
132	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2015, 16, 505-512.	0.7	40
133	Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2015, 29, 480-484.	0.9	28
134	Major predictors of portal hypertensive enteropathy in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 124-130.	1.4	23
135	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 619-627.	1.4	20
136	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , 2015, 84, 1540-1545.	1.2	16
137	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. <i>Journal of Hepatology</i> , 2015, 63, 554-563.	1.8	29
138	Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 726-732.	1.4	18
139	Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. <i>Hepatology Research</i> , 2015, 45, 378-386.	1.8	68
140	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , 2015, 25, 3272-3281.	2.3	19
141	Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2015, 33, 627-635.	1.0	11
142	Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice. <i>Journal of Virology</i> , 2015, 89, 10087-10096.	1.5	23
143	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 516-534.	2.3	67
144	Differences in serum microRNA profiles in hepatitis B and C virus infection. <i>Journal of Infection</i> , 2015, 70, 273-287.	1.7	52

#	ARTICLE	IF	CITATIONS
145	Role of conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	1.8	40
146	Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. <i>PLoS ONE</i> , 2015, 10, e0130022.	1.1	28
147	Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib. <i>Hepatology Research</i> , 2014, 44, 1320-1328.	1.8	10
148	Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1035-1042.	1.4	19
149	Is small-bowel capsule endoscopy effective for diagnosis of esophagogastric lesions related to portal hypertension?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 511-516.	1.4	19
150	Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. <i>Hepatology Research</i> , 2014, 44, 740-749.	1.8	29
151	Surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy. <i>Hepatology Research</i> , 2013, 43, 249-254.	1.8	8
152	Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1834-1841.	1.4	18
153	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. <i>Journal of Gastroenterology</i> , 2013, 48, 847-855.	2.3	19
154	Usefulness of multi-detector row computed tomography for management of duodenal varices by emergency balloon-occluded retrograde transvenous obliteration. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 243-247.	0.4	1
155	Small Bowel Abnormalities in Patients with Compensated Liver Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1390-1396.	1.1	30
156	Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects?. <i>Hepatology Research</i> , 2013, 43, 717-727.	1.8	28
157	Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 530-536.	1.4	82
158	HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e84226.	1.1	35
159	Evaluation of the mRECIST and $\alpha$ -Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib. <i>Oncology</i> , 2012, 83, 192-200.	0.9	66
160	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1850-1857.	1.4	45
161	Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 418-425.	0.7	31
162	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. <i>Hepatology</i> , 2012, 56, 555-566.	3.6	43

#	ARTICLE	IF	CITATIONS
163	Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 204-209.	0.4	0
164	Recent trend of clinical features in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 368-375.	1.8	82
165	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- $\alpha$ for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. <i>Hepatology Research</i> , 2012, 42, 442-453.	1.8	27
166	Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <i>Hepatology Research</i> , 2012, 42, 1065-1072.	1.8	56
167	Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. <i>Nature Genetics</i> , 2011, 43, 797-800.	9.4	156
168	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon sensitivity determining region. <i>Hepatology Research</i> , 2011, 41, 1126-1131.	1.8	2
169	Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. <i>Hepatology Research</i> , 2011, 41, 1046-1056.	1.8	4
170	Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. <i>Journal of Gastroenterology</i> , 2011, 46, 799-808.	2.3	24
171	Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. <i>Journal of Surgical Oncology</i> , 2011, 104, 3-9.	0.8	24
172	Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1117-1122.	1.4	16
173	Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 597-604.	1.4	72
174	Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1219-1225.	0.2	15
175	Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices. <i>European Journal of Radiology</i> , 2010, 76, 239-245.	1.2	12
176	Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. <i>Hepatology Research</i> , 2010, 40, 1082-1091.	1.8	7
177	Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 1195-1203.	1.8	21
178	Evaluation of Patients with Esophageal Varices After Endoscopic Injection Sclerotherapy Using Multiplanar Reconstruction MDCT Images. <i>American Journal of Roentgenology</i> , 2009, 192, 122-130.	1.0	11
179	Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2009, 44, 492-502.	2.3	56
180	Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 687-694.	0.9	23

#	ARTICLE	IF	CITATIONS
181	The first Japanese case of COACH syndrome. <i>Hepatology Research</i> , 2009, 39, 318-323.	1.8	2
182	Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2008, 43, 550-557.	2.3	36
183	Combination Therapy of Oral Fluoropyrimidine Anticancer Drug S-1 and Interferon Alpha for HCC Patients with Extrahepatic Metastases. <i>Oncology</i> , 2008, 75, 8-16.	0.9	19
184	Balloon-Occluded Retrograde Transvenous Obliteration for Portal-Systemic Encephalopathy due to Superior Mesenteric-Caval Shunt via the Right Gonadal Vein. <i>Internal Medicine</i> , 2007, 46, 1479-1480.	0.3	5
185	Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 414.	1.4	368
186	Similar effects of recombinant interferon- $\gamma$ 2b and natural interferon- $\gamma$ when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 070908015728003-???	1.9	34
187	The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology</i> , 2007, 42, 663-672.	2.3	88
188	Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2007, 42, 845-853.	2.3	52
189	Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 5188.	1.4	28
190	Effects of a 24-week course of interferon- $\alpha$ therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 5343.	1.4	40
191	Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Fundal Varices with Hemorrhage. <i>American Journal of Roentgenology</i> , 2002, 178, 1167-1174.	1.0	142
192	Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2002, 184, 284-290.	0.9	62
193	Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 847-854.	0.2	74
194	Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 0, , .	4.2	3
195	Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection. <i>Journal of Gastroenterology</i> , 0, , .	2.3	0